These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 27102581)

  • 1. Dose-response relationship between sulfonylureas and major adverse cardiovascular events in elderly patients with type 2 diabetes.
    Abdelmoneim AS; Eurich DT; Senthilselvan A; Qiu W; Simpson SH
    Pharmacoepidemiol Drug Saf; 2016 Oct; 25(10):1186-1195. PubMed ID: 27102581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of acute coronary events associated with glyburide compared with gliclazide use in patients with type 2 diabetes: a nested case-control study.
    Abdelmoneim AS; Eurich DT; Gamble JM; Johnson JA; Seubert JM; Qiu W; Simpson SH
    Diabetes Obes Metab; 2014 Jan; 16(1):22-9. PubMed ID: 23802997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adverse cardiovascular events during treatment with glyburide (glibenclamide) or gliclazide in a high-risk population.
    Juurlink DN; Gomes T; Shah BR; Mamdani MM
    Diabet Med; 2012 Dec; 29(12):1524-8. PubMed ID: 22913620
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacologic Differences of Sulfonylureas and the Risk of Adverse Cardiovascular and Hypoglycemic Events.
    Douros A; Yin H; Yu OHY; Filion KB; Azoulay L; Suissa S
    Diabetes Care; 2017 Nov; 40(11):1506-1513. PubMed ID: 28864502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative cardiovascular safety of insulin secretagogues following hospitalization for ischemic heart disease among type 2 diabetes patients: a cohort study.
    Huang Y; Abdelmoneim AS; Light P; Qiu W; Simpson SH
    J Diabetes Complications; 2015 Mar; 29(2):196-202. PubMed ID: 25534984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Hypoglycemic Risk of Glyburide (Glibenclamide) Compared with Modified-Release Gliclazide.
    Clemens KK; McArthur E; Dixon SN; Fleet JL; Hramiak I; Garg AX
    Can J Diabetes; 2015 Aug; 39(4):308-16. PubMed ID: 25840942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association Between Specificity of Sulfonylureas to Cardiac Mitochondrial KATP Channels and the Risk of Major Adverse Cardiovascular Events in Type 2 Diabetes.
    Wang MT; Huang YL; Lai JH; Lee CH; Wang PC; Pan HY; Lin C; Liou JT; Hsu YJ
    Diabetes Care; 2022 May; 45(5):1276-1287. PubMed ID: 35294529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sulfonylureas as initial treatment for type 2 diabetes and the risk of adverse cardiovascular events: A population-based cohort study.
    Filion KB; Douros A; Azoulay L; Yin H; Yu OH; Suissa S
    Br J Clin Pharmacol; 2019 Oct; 85(10):2378-2389. PubMed ID: 31276600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Use of Glyburide Compared With Other Sulfonylureas and the Risk of Cancer in Patients With Type 2 Diabetes.
    Tuccori M; Wu JW; Yin H; Majdan A; Azoulay L
    Diabetes Care; 2015 Nov; 38(11):2083-9. PubMed ID: 26341130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metformin in combination with various insulin secretagogues in type 2 diabetes and associated risk of cardiovascular morbidity and mortality--a retrospective nationwide study.
    Mogensen UM; Andersson C; Fosbøl EL; Schramm TK; Vaag A; Scheller NM; Torp-Pedersen C; Gislason G; Køber L
    Diabetes Res Clin Pract; 2015 Jan; 107(1):104-12. PubMed ID: 25458330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mortality outcomes of different sulphonylurea drugs: the results of a 14-year cohort study of type 2 diabetic patients.
    Bo S; Castiglione A; Ghigo E; Gentile L; Durazzo M; Cavallo-Perin P; Ciccone G
    Eur J Endocrinol; 2013 Jul; 169(1):117-26. PubMed ID: 23660643
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glibenclamide-related excess in total and cardiovascular mortality risks: data from large Ukrainian observational cohort study.
    Khalangot M; Tronko M; Kravchenko V; Kovtun V
    Diabetes Res Clin Pract; 2009 Dec; 86(3):247-53. PubMed ID: 19796836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glyburide use is associated with a greater likelihood of mortality or rehospitalization after acute coronary syndrome compared to gliclazide use in adults with type 2 diabetes: A cohort study.
    Long W; Light PE; Simpson SH
    Diabetes Obes Metab; 2024 Nov; 26(11):5408-5419. PubMed ID: 39248222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of insulin dosage with mortality or major adverse cardiovascular events: a retrospective cohort study.
    Gamble JM; Chibrikov E; Twells LK; Midodzi WK; Young SW; MacDonald D; Majumdar SR
    Lancet Diabetes Endocrinol; 2017 Jan; 5(1):43-52. PubMed ID: 27865756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HYPOGLYCEMIA INDUCED BY ANTIDIABETIC SULFONYLUREAS.
    Confederat L; Constantin S; Lupaşcu F; Pânzariu A; Hăncianu M; Profire L
    Rev Med Chir Soc Med Nat Iasi; 2015; 119(2):579-84. PubMed ID: 26204670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study.
    Simpson SH; Majumdar SR; Tsuyuki RT; Eurich DT; Johnson JA
    CMAJ; 2006 Jan; 174(2):169-74. PubMed ID: 16415461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is gliclazide a sulfonylurea with difference? A review in 2016.
    Singh AK; Singh R
    Expert Rev Clin Pharmacol; 2016 Jun; 9(6):839-51. PubMed ID: 26924475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rates of hypoglycemia in users of sulfonylureas.
    van Staa T; Abenhaim L; Monette J
    J Clin Epidemiol; 1997 Jun; 50(6):735-41. PubMed ID: 9250272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of mortality and cardiovascular event risk associated with various insulin secretagogues: A nationwide real-world analysis.
    Huang HK; Yeh JI
    Diabetes Res Clin Pract; 2019 Jun; 152():103-110. PubMed ID: 31108137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucose-lowering with exogenous insulin monotherapy in type 2 diabetes: dose association with all-cause mortality, cardiovascular events and cancer.
    Holden SE; Jenkins-Jones S; Morgan CL; Schernthaner G; Currie CJ
    Diabetes Obes Metab; 2015 Apr; 17(4):350-62. PubMed ID: 25399739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.